Completed

Phase 3
Age: 30Years - 64Years
MALE
NCT00000482

Coronary Drug Project

Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2013-11-26

N/A

Participants Needed

N/A

Research Sites

1039 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.

CONDITIONS

Official Title

Coronary Drug Project

Who Can Participate

Age: 30Years - 64Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

Men, ages 30-64. Three months beyond most recent myocardial infarction.

Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Site Locations not provided

Location information for this trial is currently unavailable.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

N/A

Primary Purpose

PREVENTION

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here